The US Food and Drug Administration (FDA) has flagged issues at Strides Pharma's Bangalore facility, listing five key concerns in a Form 483 notice. Strides Pharma assures prompt action to address these issues and keep stakeholders informed.

Strides Pharma has received approval from the National Company Law Tribunal (NCLT) to spin off Arcus Labs, creating a new entity, Pivot Path, focused on life sciences and digital innovation. Strides will maintain full ownership of Pivot Path, positioning itself for further growth in these areas.

The regulatory board has given the green light for Arco Lab's Life Sciences and Digital Innovation divisions to be spun off as a new entity called Pivot Path, set to launch on April 10, 2025.

Cohance Life experiences a 8% growth in its stock price, while Strides Pharma faces a drop of more than 9%. The contrasting fortunes between the two companies suggest different market reactions to their recent performances.

Strides Pharma plans to boost its North American revenue to a range of $375 million - $400 million by the fiscal year 2028, aiming for enhanced profitability in the process.

Strides Pharma's Q4 profit skyrocketed by 51%, reaching INR 129.2 crore, primarily due to robust growth outside the US. The company reported a revenue increase of 11.2% YoY to INR 1,323.4 crore and declared a final dividend of INR 5 per share, with net debt standing at INR 1,436.5 crore.

Companies like IOC, Astral, Zydus Wellness, Strides Pharma, JSW Cement, GE Vernova, DOMS Industries, and Afcons Infra will be reporting their Q4 results today, shedding light on their financial performance for the quarter. Investors will closely watch these announcements to assess the companies' progress.

Strides Pharma aims to reach a $400 million revenue mark in North America by fiscal year 2028, even amidst current obstacles. The company expects a resurgence of growth in the second half of this fiscal year as circumstances enhance.

Strides Pharma reported a significant 50% increase in FY26 operational profit year-over-year, reaching approximately 5.18 billion INR, while revenue grew by 6.4% to around 48.6 billion INR. The company's performance was primarily driven by a 21% growth in sales from markets outside of the US. Despite challenges in the US market, revenues remained stable at 284 million INR.

Strides Pharma has proposed a Rs. 5 per share dividend for the fiscal year 2026, subject to approval at the upcoming Annual General Meeting (AGM). The exact record date for receiving the dividend is yet to be announced.

Strides Pharma's Q4 profits experienced a significant increase, jumping 55% year-over-year to reach approximately INR 1.27 billion compared to the previous year's INR 822 million.

Strides Pharma has announced a dividend of ₹5 per share, a move that could potentially benefit its shareholders with an additional income.

Strides Pharma is set to gain from Sandoz's contributions starting in the second half of their financial year 2026-27, which may potentially boost their revenue and growth prospects.

Strides Pharma Science Ltd is set to convene on May 18, 2026, for approval of their FY26 financial results. There's a possibility that the board will propose a final dividend distribution as well. The trading window will stay closed for 48 hours following the announcement of the results.